Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Operating Expenses (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Operating Expenses for 15 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 48.27% year-over-year to $3.7 million, compared with a TTM value of $14.9 million through Sep 2025, up 19.55%, and an annual FY2024 reading of $11.9 million, down 22.38% over the prior year.
  • Operating Expenses was $3.7 million for Q3 2025 at BioRestorative Therapies, up from $3.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $15.1 million in Q1 2021 and bottomed at $2.5 million in Q3 2024.
  • Average Operating Expenses over 5 years is $4.5 million, with a median of $3.7 million recorded in 2025.
  • The sharpest move saw Operating Expenses skyrocketed 1683.77% in 2021, then plummeted 66.36% in 2022.
  • Year by year, Operating Expenses stood at $4.0 million in 2021, then rose by 16.72% to $4.7 million in 2022, then plummeted by 30.85% to $3.2 million in 2023, then dropped by 15.74% to $2.7 million in 2024, then skyrocketed by 35.9% to $3.7 million in 2025.
  • Business Quant data shows Operating Expenses for BRTX at $3.7 million in Q3 2025, $3.6 million in Q2 2025, and $4.8 million in Q1 2025.